Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894564 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
A Phase 3 study of Covid19, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,208
- Enrollment target
- 20
- Study locations
NCT05894564 is a Phase 3 study of Covid19 that has completed, run by Susanna Naggie, MD. The registered enrollment target is 1,208 participants, below the 2,689-participant average among 94 other Covid19 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05894564, a Phase 3 study of Covid19, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,208 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fluvoxamine
Study Locations (20)
Florida
- Arena Medical Group - Deerfield Beach
- Lupus Foundation of Gainesville - Gainesville
- University of Florida Health - Gainesville
- L and A Morales Healthcare, Inc - Hialeah
- University of Florida-JAX-ASCENT - Jacksonville
- AMRON Vitality and Wellness Center, LLC - Jacksonville
- Sunshine Walk In Clinic - Lake Mary
- Lakeland Regional Medical Center - Lakeland
- Jackson Memorial Hospital - Miami
- University of Miami - Miami
Arizona
- Lamb Health, LLC - Gilbert
- First Care Medical Clinic - Mesa
- Trident Health Center - Peoria
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Assuta Family Medical Group APMC - North Hollywood
- Stanford - Palo Alto
Colorado
- Doctors Medical Group of Colorado Springs, P.C. - Colorado Springs
- Pine Ridge Family Medicine Inc. - Colorado Springs
Connecticut
- Tabitha B. Fortt, M.D., LLC - Stamford
District of Columbia
- George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894564
The ClinicalTrials.gov registry entry for NCT05894564 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,689-participant average among 94 other Covid19 trials with a reported enrollment target (55% lower). The listed sponsor is Susanna Naggie, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05894564 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05894564 about?
NCT05894564 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT05894564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,208 participants. The study started on 2022-08-25. Estimated completion is 2023-05-30.
What conditions does trial NCT05894564 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT05894564?
The interventions under investigation include: Placebo (OTHER), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT05894564?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05894564 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Aggrenox To Treat Acute Covid-19
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Contrast Enhanced Ultrasound in COVID-19
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.